Application of vinpocetine in preparation of medicament for preventing and/or treating mountain sickness caused by rush entry into plateaus

A technology of vinpocetine and altitude sickness, applied in the field of biomedicine, can solve problems such as no related reports

Active Publication Date: 2019-03-29
中国人民解放军总医院第七医学中心
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no relevant report on the study of vinpocetine tablets in the treatment of cerebral edema and myocardial edema after rapid entry into high altitude hypobaric hypoxic environment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of vinpocetine in preparation of medicament for preventing and/or treating mountain sickness caused by rush entry into plateaus
  • Application of vinpocetine in preparation of medicament for preventing and/or treating mountain sickness caused by rush entry into plateaus
  • Application of vinpocetine in preparation of medicament for preventing and/or treating mountain sickness caused by rush entry into plateaus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1, the application of vinpocetine in the preparation of the medicine for the prevention and treatment of altitude sickness caused by rapid advance to the plateau

[0039] 1. Experimental materials and methods

[0040] 1. Experimental materials: six-week-old SPF grade SD rats, weighing 200±20g, male.

[0041] 2. Experimental grouping: SD rats were randomly divided into plateau hypoxia experimental group, vinpocetine intervention group and normal pressure and normal oxygen control group by random number table method. 18 animals per group. The treatment methods for each group are as follows:

[0042] Plateau hypoxic experiment group (referred to as hypoxic group or HH group): the experimental cabin (Guizhou Fenglei Aviation Ordnance Co., Ltd.) was used to simulate plateau low pressure and hypoxic conditions. SD rats were placed in the experimental cabin for 7 days under high altitude hypobaric hypoxia treatment. Parameter setting of the experimental cabin: t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of vinpocetine in preparation of a medicament for preventing and / or treating acute mountain sickness caused by rush entry into plateaus, and further discloses application of vinpocetine in preparation of a medicament for preventing and / or treating myocardial tissue edema and / or brain tissue edema, myocardial tissue inflammatory reaction and / or brain tissue inflammatory reaction caused by low-pressure and low-oxygen environments at the rush entry into plateaus. The invention explores a prevention and treatment effect of vinpocetine on the brain tissue and myocardial tissue edema caused by low pressure and low oxygen at the rush entry into plateaus, and the results show that vinpocetine can down-regulate the expression level of aquaporin genes AQP1 in myocardial tissues and brain tissues under low-pressure and low-oxygen conditions of the plateaus to reduce brain edema and myocardial edema caused by low pressure and low oxygen of the plateaus. The invention simulates the plateau environment at the altitude of 7000m and observes the protective effect of vinpocetine on the myocardial edema and brain edema of rats induced by the low pressure and low oxygen of the plateaus, thereby providing new application and new targets for drug intervention for clinical application of vinpocetine.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of vinpocetine in the preparation of medicines for preventing and / or treating altitude sickness caused by rapidly advancing to high altitudes, in particular to the application of vinpocetine in the preparation of prevention and / or treatment of rapidly advancing to high altitude low-pressure hypoxic environments The application of drugs that cause acute mountain sickness. Background technique [0002] The low-pressure and low-oxygen environment of the plateau above 3000m will have a great impact on human health, especially when people who have not adapted to exercise quickly enter the plateau from the plain, they are very prone to acute mountain sickness (Acute mountain sickness, AMS), and the treatment is not timely. It can further develop into life-threatening conditions such as high altitude pulmonary edema (High attitude pulmonary edema, HAPE) an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4375A61P39/00A61P9/00A61P25/00
CPCA61K31/4375A61P9/00A61P25/00A61P39/00
Inventor 施冰薛大卫
Owner 中国人民解放军总医院第七医学中心
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap